Laquinimod – Tevas självklara efterträdare!
2012-03-09 14:18Please note: Community posts are written by its members and not by Redeye’s research department. As a reader you’re always encouraged to critically analyze the content.
Artikel idag
Teva and Active Biotech are also looking to bring their new MS treatment Laquinimod to the market for 2012. The drug is forecast to be making $600 million in peak annual sales, but received a blow when a recent Phase III trial showed that it failed to reduce relapse rates in MS patients compared to placebo.
Teva is looking to the drug as a successor to its current injectable MS drug Copaxone (glatiramer acetate), which made the firm $3.3 billion last year.
http://www.inpharm.com/news/171690/major-new-drugs-2012
Scrolla ner på sidan så får du ovan skrivna text.
Aktien kommer inte att stanna vid 170 SEK
– 300 SEK är mer tänkbart...
Jag kan bara säga: KÖP!
Mvh
M.